Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
<< View all publications

OncologyLive

Stereotactic Radiosurgery Can Improve Control of Brain Metastases
Stereotactic Radiosurgery Can Improve Control of Brain Metastases
Vol. 20/No. 18   >   Features
Growing Body of Evidence Supports Use of HIPEC in Ovarian Cancer
Growing Body of Evidence Supports Use of HIPEC in Ovarian Cancer
Vol. 20/No. 17   >   Partner Perspective
Lasofoxifene Explored in ESR1-Mutated ER+/HER2- Breast Cancer
Lasofoxifene Explored in ESR1-Mutated ER+/HER2- Breast Cancer
Vol. 20/No. 17   >   Features
Search for New Prostate Cancer Targets Yields a Profusion of Options
Search for New Prostate Cancer Targets Yields a Profusion of Options
Vol. 20/No. 17   >   Pathways
Expert Anticipates Expansion of Targeted Therapies Aimed at Resistance in Breast Cancer
Expert Anticipates Expansion of Targeted Therapies Aimed at Resistance in Breast Cancer
Vol. 20/No. 17   >   Features
Molecular Testing Enhances Decision-Making Process in Thyroid Cancer of Indeterminate Malignancy
Molecular Testing Enhances Decision-Making Process in Thyroid Cancer of Indeterminate Malignancy
Vol. 20/No. 17   >   Features
An Instinct for Innovation Drives Robert's Melanoma Research
An Instinct for Innovation Drives Robert's Melanoma Research
Vol. 20/No. 17   >   Features
Signs Point to Better Market Conditions for Biosimilars
Signs Point to Better Market Conditions for Biosimilars
Vol. 20/No. 17   >   Features
The New Ovarian Cancer Landscape: Many Questions, Much Hope
The New Ovarian Cancer Landscape: Many Questions, Much Hope
Vol. 20/No. 17   >   Cover Story
CDK 4/6 Inhibitor Combos Could Have Lasting Benefits in ER+ Metastatic Breast Cancer
CDK 4/6 Inhibitor Combos Could Have Lasting Benefits in ER+ Metastatic Breast Cancer
Vol. 20/No. 17   >   Features
Next Page >>
Publication Bottom Border
Border Publication
 
x